Table 2.
Clinical characteristics of 11 patients related to COVID-19
| Characteristics related to COVID-19 | n (%) |
|---|---|
| History of exposure to Huanan market | 0 (0.0) |
| Positive postoperative exposure history | 10 (90.9) |
| Symptom of onset | |
| Dry cough | 1 (9.1) |
| Dyspnea | 2 (18.2) |
| Fever | 8 (72.7) |
| Sign and symptom after onset | |
| Fever | 11 (100.0) |
| Maximum temperature, °C | |
| 38-39 | 6 (54.5) |
| ≥39 | 5 (45.5) |
| Dyspnea | 11 (100.0) |
| Chest tightness | 10 (90.9) |
| Fatigue | 10 (90.9) |
| Dry cough | 9 (81.8) |
| Loss of appetite | 6 (54.5) |
| Nausea | 6 (54.5) |
| Headache | 6 (54.5) |
| Cough with sputum | 4 (36.4) |
| Diarrhea | 3 (27.3) |
| Dizziness | 2 (18.2) |
| Rhinorrhea | 1 (9.1) |
| Pleural effusion | 6 (54.5) |
| Laboratory results | |
| Leucocytes (reference 3.5-9.5 × 109 per L) | |
| Leukocytosis | 11 (100.0) |
| Leukopenia (sequential to leukocytosis) | 2 (18.2) |
| Lymphocyte count (reference 1.1-3.2 × 109 per L) | |
| Lymphopenia | 10 (90.9) |
| Eosinophil count (reference 0.02-0.52 × 109 per L) | |
| Eosinopenia | 11 (100.0) |
| Persist eosinopenia during disease course | 9 (81.8) |
| Elevated ALT (reference ≤41 U/L) | 8 (72.7) |
| Elevated AST (reference ≤40 U/L) | 7 (63.6) |
| Elevated creatinine (reference 59-104 μmol/L) | 0 (0.0) |
| Elevated LDH (reference 135-225 U/L) | 11 (100.0) |
| Clinical outcome | |
| Recovery | 8 (72.7) |
| Death | 3 (27.3) |
| Clinical pattern of COVID-19 | |
| Nonsevere | 4 (36.4) |
| Severe | 4 (36.4) |
| Critical | 3 (27.3) |
Detailed information for each patient is listed in supplementary table. COVID-19, Coronavirus disease 2019; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase.